51 – 60 of 69
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2006
-
Mark
Perinatal events and the risk of developing primary sclerosing cholangitis
(
- Contribution to journal › Article
- 2005
-
Mark
High-dose ursodeoxycholic acid in primary sclerosing cholangitis: A 5-year multicenter, randomized, controlled study
(
- Contribution to journal › Article
-
Mark
Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study
(
- Contribution to journal › Article
- 2004
-
Mark
Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease: elevated oxidized low-density lipoprotein and the anti-inflammatory effect of atorvastatin.
(
- Contribution to journal › Article
-
Mark
Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease : Elevated oxidized low-density lipoprotein and the anti-inflammatory effect of artorvastatin
(
- Contribution to journal › Article
- 2003
-
Mark
Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives
(
- Contribution to journal › Article
- 2002
-
Mark
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis
(
- Contribution to journal › Article
-
Mark
Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC)
(
- Contribution to journal › Article
-
Mark
High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection. A randomized, double blind, placebo controlled trial of interferon alpha-2b with and without ribavirin.
(
- Contribution to journal › Article
-
Mark
Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis.
(
- Contribution to journal › Article